Shire to take on hemophilia marketing with long-sought Baxalta buy

Baxalta ($BXLT) and its portfolio of hemophilia meds are finally destined to join the fold at Shire ($SHPG). Monday, the two companies announced a $32 billion tie-up after a months-long pursuit by the Dublin drugmaker. More from FiercePharma

Suggested Articles

Only months after a game-changing new approval for Vascepa, Amarin has lost a key fight over its patents—and now it's scrambling to respond.

Move over, Roche. There’s a new small cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.